TGFB1 and systemic sclerosis: Although TGF-β is a key mediator of fibrogene-sis[66,96–97], and its activity associated with fibrosis in SSc makes it an attractive therapeutic target, the pleiotropic functions of TGF-β make non-selective blocking of its signaling potentially dangerous[66,98].